Sukumar Nagendran

Recently the Chief Medical Officer at AveXis Inc. and member of senior executive team responsible for launching the firm’s successful IPO and subsequent $8B acquisition by Novartis in 2018. He was responsible for working with the FDA to obtain BTD (breakthrough therapy designation), PRIME designation in the EU and SakiGake designation in Japan for AVXS-101 gene therapy for SMA-1. He has over 30 years of experience with gene therapy development, clinical development strategy, medical affairs and diagnostics. He currently serves on board of Solid Biosciences, advisor to Chardan & Encoded Therapeutics